NRXPW
NRX Pharmaceuticals, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 30 ▼ Short interest jumps 1265.7% to 30.5K
- May 15 ▲ Short interest falls 83.1% to 5.2K
- May 22 ▼ Nasdaq filed a Form 25-NSE to remove from listing and deregister the…
- Jun 2 ▼ NRx Pharmaceuticals filed a preliminary prospectus supplement for an…
- Jun 3 ▼ NRx Pharmaceuticals is conducting a firm-commitment underwritten pub…
- Jun 4 ▼ NRx Pharmaceuticals closed a firm-commitment underwritten public off…
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q1 2026: 0 added (0 new), 1 trimmed or exited.
- Short sellersCOVERING
Short interest −83.1% to 5.2K shares. 1.0 days to cover.
- TrendDOWNTREND
23% below its 50-day average.
Who's buying
13F· Q1 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | NEAR_EXIT | Not reported |
| UBS Group AG | DOUBLED | $131.00 |
| UBS Group AG | NEAR_EXIT | $1.00 |
| UBS Group AG | ADD | $128.00 |
| WOLVERINE ASSET MANAGEMENT LLC | DOUBLED | $1.4K |
| UBS Group AG | TRIM | $73.00 |
| WOLVERINE ASSET MANAGEMENT LLC | TRIM | $664.00 |
| UBS Group AG | TRIM | $501.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | None | None | No data | $1.1M |
| Next Q | None | None | No data | $1.1M |
| Current FY | None | None | No data | $4.3M |
| Next FY | None | None | No data | $301.7M |
Washington
Short side
FINRA· May 15, 2026SecBot reports
4 filings · 0 bullish · 4 bearish- BEARISH 8-KJun 4, 2026
NRx Pharmaceuticals closed a firm-commitment underwritten public offering of 5,714,286 shares of…
The dilutive offering at a steep discount signals urgent capital needs for a clinical-stage biopharma with negative book value and a going-concern audit opinion. Monitor for further cash burn and…
- BEARISH 424B5Jun 3, 2026
NRx Pharmaceuticals is conducting a firm-commitment underwritten public offering of 5,714,286…
The steep discount and significant dilution signal near-term selling pressure. Monitor for potential further capital needs given the going-concern audit language and the company's clinical-stage…
- BEARISH 424B5Jun 2, 2026
NRx Pharmaceuticals filed a preliminary prospectus supplement for an underwritten firm-commitment…
Monitor for the final pricing supplement to determine share count, price, and net proceeds. The dilutive raise for a going-concern clinical-stage company with negative book value is a clear negative…
- BEARISH 25-NSEMay 22, 2026
Nasdaq filed a Form 25-NSE to remove from listing and deregister the warrants (NRXPW) of NRX…
Holders of NRXPW warrants should expect zero residual value post-delisting. Monitor for any final redemption payment from the company, but the filing indicates the securities are matured/retired. No…
All NRXPW filing & press-release reports (4)
- 8-K reportJun 4, 2026
- 424B5 reportJun 3, 2026
- 424B5 reportJun 2, 2026
- 25-NSE reportMay 22, 2026